Emergent BioSolutions (EBS) Misses Q4 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.23 +0.48%
EPS Growth %: -138.7%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
UTMD, GCBC, ORPB, More
EPS Growth %: -138.7%
Financial Fact:
Provision for (benefit from) income taxes: 13.17M
Today's EPS Names:
UTMD, GCBC, ORPB, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $1.57, $0.16 worse than the analyst estimate of $1.73. Revenue for the quarter came in at $360.4 million versus the consensus estimate of $357.41 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Chemung Financial (CHMG) Tops Q3 EPS by 69c
- Investar Holding (ISTR) Tops Q3 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
